SCHEMBL7674886

SCHEMBL7674886

COc1cccc(CO)c1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
IDO1 P14902 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
ALOX5 P09917 1/20 0.42
PTGS2 P35354 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9211153 0.82 IDO1 (0.42) IDO1MEN1KMT2AALDH1A1KDM4E
SCHEMBL31200741 0.82 GABRA1 (0.64) IDO1MEN1KMT2AALOX5PTGS2
SCHEMBL12806081 0.82 GABRA1 (0.64) IDO1MEN1KMT2AALOX5PTGS2
SCHEMBL16961825 0.81 ALDH1A1 (0.45) MEN1KMT2AALDH1A1TP53MAPT
SCHEMBL16957276 0.80 HTR1A (0.40) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL31614197 0.80 IDO1 (0.41) IDO1MEN1KMT2AALDH1A1KDM4E
SCHEMBL27761667 0.80 TAAR1 (0.50) IDO1MEN1KMT2AALDH1A1MAPT
SCHEMBL7674880 0.80 GABRA1 (0.45) IDO1MEN1KMT2AALDH1A1KDM4E
SCHEMBL16954516 0.79 IRAK4 (0.39) MEN1KMT2APDCD1CD274ALDH1A1
SCHEMBL17820 0.79 IDO1 (0.57) PDE4APDE4BPDE4CPDE4DIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2026-01-29 US disclosed
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2025-06-12 US disclosed
EP-3860975-B1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS INC (US) 2023-10-18 EP disclosed
EP-3860975-B1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS INC (US) 2023-10-18 EP disclosed
CN-114829362-A Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatom and used as SHP2 inhibitor 成都倍特药业股份有限公司 2022-07-29 CN disclosed
EP-3860975-A1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE Global Blood Therapeutics, Inc. (US) 2021-08-11 EP disclosed
WO-2021115286-A1 SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR 成都倍特药业股份有限公司 2021-06-17 WO disclosed
WO-2021115286-A1 SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR 成都倍特药业股份有限公司 2021-06-17 WO disclosed
US-11014884-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
US-20200140384-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2020-05-07 US disclosed
WO-2020072377-A1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-04-09 WO disclosed
WO-2020072377-A1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-04-09 WO disclosed
US-9796735-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2017-10-24 US disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds CYP1B1, CYP1A1, PAH PDE4A 2158/4885PDE4B 1643/4885PDE4C 2716/4885
US-11014884-B2 Modulators of hemoglobin HBG1, HBG2, HBB PDE4A 796/4885PDE4B 1610/4885PDE4C 763/4885
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds KAT2B, KAT2A, KAT6A PDE4A 3924/4885PDE4B 3223/4885PDE4C 4125/4885
US-20200140384-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB PDE4A 796/4885PDE4B 1610/4885PDE4C 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.